相关实验视频
Updated: May 25, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
973
安洛提尼布诱导的恶性鼻综合征:两个病例报告
Cheng-Feng Fu1, Li-Fen Yang1, Lei Tian1
1Department of Oncology, Tongren People's Hospital, Tongren 554300, Guizhou Province, China.
World journal of clinical cases
|February 27, 2025
概括
对非小细胞肺癌的安洛尼布治疗可能会导致恶性鼻综合征 (SSS). 对接受anlotinib的患者来说,密切的心脏监测至关重要,以检测和管理这种潜在的副作用.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
背景情况:
- 安洛丁尼布是一种用于治疗非小细胞肺癌的氨酸激酶抑制剂.
- 病鼻综合征 (SSS) 是一种影响心率调节的心律失常.
研究的目的:
- 报告与anlotinib治疗的非小细胞肺癌患者中第一个已知的SSS病例.
- 强调在安洛丁尼布治疗期间心脏监测的重要性.
- 讨论关于安洛尼布诱导的SSS的个性化管理策略.
主要方法:
- 两名非小细胞肺癌患者的病例报告.
- 患者在安洛尼布治疗后出现了SSS症状.
- 通过心电图证实了诊断; 治疗有所不同.
主要成果:
- 两名患者在15个月和5个月的anlotinib后出现昏睡和心.
- 电心电图证实了这两种病例的鼻综合征.
- 一名患者接受了心脏起器,另一名患者停止了安洛替尼的治疗,症状消失.
结论:
- 安洛丁尼布可以诱导恶心鼻综合征.
- 警的心脏监测对于接受anlotinib的患者至关重要.
- 需要量身定制的治疗方法来管理anlotinib诱导的SSS.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
172
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
172

